RLAY · Relay Therapeutics, Inc.

The thesis

Relay Therapeutics is a clinical-stage cancer drug developer whose value rests on one molecule, zovegalisib (also called RLY-2608), and the third-quarter report on 4 November 2026 is the next event that tests the case. The shares closed at $19.69 on 28 October 2026, 5.1% below the 52-week high of $20.75, after closing at $17.30 on 15 October 2026 (adjusted daily closes).

The narrative is maturing: the analyst initiations from JPMorgan and Canaccord Genuity date to 8 July 2026 and 16 July 2026, and company news since then is limited to the earnings-date announcement of 28 October 2026. The next hard clinical readout is in 2027, so the shares trade on a quantified ReDiscover-2 Phase 3 enrollment update (guided for year-end 2026), cash, and share supply.

Conviction stays low. The rebound is a price move, and no new clinical, financial or analyst fact has arrived to change the evidence. The close of $19.69 now sits above the $19.40 price at which a large holder sold in August, and the 14-day relative strength index reads 66.7, close to the 70 level that is conventionally read as stretched.

Bullish and bearish views on Relay Therapeutics, Inc.

The bull case on Relay Therapeutics, Inc. (RLAY), in brief: Cash covers the Phase 3 program. The bear case: A large holder sold at $19.40.

Bull case

• Cash covers the Phase 3 program. Relay reported $910.9 million of cash, cash equivalents and investments at 30 June 2026 and guided a runway into 2029 in its 6 August 2026 second-quarter release. The runway is management's forecast.
• Regulatory recognition exists. The FDA granted zovegalisib Breakthrough Therapy designation for PIK3CA-mutant, HR+/HER2- advanced breast cancer, announced in February 2026 (company release). Relay's 16 March 2026 presentation reported median progression-free survival of 11.1 months for zovegalisib plus fulvestrant at the Phase 3 dose.
• Second indication shows early activity. In the ReInspire vascular-anomalies trial, Relay reported on 19 May 2026 that 60% of patients had a volumetric response at 12 weeks, as of the 15 April 2026 data cut-off.
• Pipeline is widening. Per the second-quarter release, Relay selected zovegalisib plus atirmociclib as its go-forward first-line triplet, with a Phase 3 expected to start in early 2027.
• Analyst targets sit above the price. JPMorgan initiated at Overweight with a $28 target on 8 July 2026 (Benzinga). Canaccord Genuity initiated with a $29 target on 16 July 2026 (Benzinga). Both exceed the $19.69 close.

Bear case

• A large holder sold at $19.40. SVF Pauling, a director-affiliated 10% owner, sold 6,000,000 shares at $19.40 on 25 August 2026, according to a Form 4 filed 28 August 2026. The 28 October 2026 close is back above that price, which is where that supply appeared last time.
• The company can issue shares at any time. The 6 August 2026 prospectus supplement expanded the at-the-market equity program to $462,978,049. Sales need no separate announcement, so the third-quarter report is the first place any use of the program since the expansion would show.
• One molecule carries the company. The breast-cancer and vascular-anomalies programs both rest on zovegalisib, and the FGFR2 drug RLY-4008 is licensed to Elevation Oncology. A safety or efficacy problem would hit both programs.
• Earnings fall six days after the last close. The report on 4 November 2026 arrives with the relative strength index at 66.7 and the shares near the $20.75 52-week high (adjusted daily closes).

Price setup

The last close was $19.69 on 28 October 2026. The 52-week high of $20.75 is 5.1% above it. The 3-month price change is 4.6%, against -9.8% on 15 October 2026.

The $19.40 sale price of 25 August 2026 sits just under the close, and the closes of $18.96 on 2 October 2026 and $17.30 on 15 October 2026 sit below it. The shares have recovered into the price range where supply from a 10% owner appeared before.

Crowding evidence observable today: a relative strength index of 66.7, an earnings date within a week, an expanded at-the-market program, and a prior large-holder sale at $19.40. No new SEC filings are listed since the August Form 4. The previous $16.00 invalidation level in the prior note is now 18.7% below the market, so the level below has been raised to the 15 October 2026 close.

Catalysts, next 30 days

• 31 December 2026: Year-end deadline for the guided ReDiscover-2 enrollment update. Falls outside the 30-day window, but the recovery case turns on it. A quantified update supports the case; an absent or vague one fails it.

Elapsed catalysts

• 4 November 2026: Third-quarter 2026 financial results and corporate highlights (company announcement dated 28 October 2026). The report updates cash, quarterly spending, and any at-the-market share sales since the August expansion. (passed 2d ago)
• Early 2027: Expected start of the first-line triplet Phase 3 (second-quarter release, 6 August 2026). (passed 92d ago)

What would change the view

The case breaks if the third-quarter report or a later filing shows heavy use of the at-the-market program, if any safety, efficacy or trial-hold disclosure for zovegalisib appears, or if the ReDiscover-2 enrollment update arrives after 31 December 2026 without numbers. A new Form 4 from SVF Pauling reporting further sales would add to the supply argument. A daily close below $17.30, the 15 October 2026 close, would return the shares to the level where the recent slide stopped.

Conviction would rise on a quantified enrollment update that shows the trial on schedule, together with a third-quarter report showing little or no share issuance.

What it trades with

Relay trades with clinical-stage oncology and the broader small- and mid-cap biotech group, which respond to interest-rate expectations and financing conditions. Its company-specific drivers are zovegalisib trial execution and share supply from the at-the-market program and large holders. The FGFR2 drug RLY-4008 is partnered with Elevation Oncology, so that company's disclosures touch the one non-zovegalisib asset.